Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rani Therapeutics Holdings (RANI) Current Deferred Revenue (2020 - 2026)

Rani Therapeutics Holdings' Current Deferred Revenue history spans 4 years, with the latest figure at $6.8 million for Q1 2026.

  • On a quarterly basis, Current Deferred Revenue changed N/A to $6.8 million in Q1 2026 year-over-year; TTM through Mar 2026 was $6.8 million, a N/A change, with the full-year FY2025 number at $8.5 million, changed N/A from a year prior.
  • Current Deferred Revenue came in at $6.8 million for Q1 2026, down from $8.5 million in the prior quarter.
  • The five-year high for Current Deferred Revenue was $8.5 million in Q4 2025, with the low at $600000.0 in Q3 2024.
  • Historically, Current Deferred Revenue has averaged $5.3 million across 3 years, with a median of $6.8 million in 2026.